Literature DB >> 27182148

Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone.

Charu Chandra Saxena1, Rajni Safaya1, Neha Kawatra Madan2, Shah Alam Khan3, Venkateswaran K Iyer1.   

Abstract

Giant cell tumor (GCT) of bone is a benign locally aggressive tumor whose biological behavior is unpredictable. Currently, there are no definitive clinical, histological, biochemical, or immunological parameters that can predict its behavior. This study was undertaken to examine whether delineation of reactive and neoplastic stromal component of GCT can help in this regard. 55 cases of GCT (30 primary, 25 recurrent) were subjected to histopathological grading, immunohistochemistry, and image analysis. Spindling of stroma was more frequent in recurrent GCT with 64% cases having more than 50% spindled stroma (p < 0.001). Number of mitosis/10 HPF and higher grade were more in recurrent GCT. Mean percentage positivity for CD68 (38.36%) and α1-ACT (70.86%) was higher in primary than recurrent GCT. PCNA and MiB-1 labeling indices were higher in recurrent (42.62% and 9.18%, respectively) than in primary group (24.75% and 7.7%, respectively). A single numerical parameter encompassing stromal cell population and its proliferation was derived as ratio of PCNA/CD68 and PCNA/α1-ACT. Both ratios were higher in recurrent (0.81 ± 0.38; 1.58 ± 1.50) than in primary GCT (0.58 ± 0.62; 0.34 ± 0.29) (p = 0.002; 0.01). On image analysis, parameters significantly different between the two groups were nuclear area and nuclear integrated optical density. It was thus concluded that recurrent GCT shows higher grade, increased mitosis, more spindling, fewer reactive components, and higher proliferation than primary GCT. Delineation of reactive component (α1-ACT positive) and proliferating component (PCNA positive cells) using immunohistochemistry with calculation of the PCNA/ACT ratio delivers more information than image analysis.

Entities:  

Keywords:  Giant cell tumor; Image analysis; Immunohistochemistry; Primary; Recurrent

Year:  2015        PMID: 27182148      PMCID: PMC4857144          DOI: 10.1016/j.jcot.2015.09.006

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  23 in total

Review 1.  Giant Cell Tumor (tumor gigantocellularis, osteoclastoma) - epidemiology, diagnosis, treatment.

Authors:  Marta Karpik
Journal:  Ortop Traumatol Rehabil       Date:  2010 May-Jun

Review 2.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.

Authors:  Christopher Martin; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2010

3.  Recurrence in giant cell tumour of bone: imaging features and risk factors.

Authors:  Cheng-Sheng Wang; Jiang-Hua Lou; Jin-Sheng Liao; Xiao-Yi Ding; Lian-Jun Du; Yong Lu; Ling Yan; Ke-Min Chen
Journal:  Radiol Med       Date:  2012-08-08       Impact factor: 3.469

4.  Prognostic factors in giant cell tumor of bone. A modified histological grading system useful as a guide to prognosis.

Authors:  S Komiya; A Inoue; M Nakashima; A Ueno; K Fujikawa; H Ikuta
Journal:  Arch Orthop Trauma Surg       Date:  1986

5.  An immunohistological study of giant-cell tumour of bone: evidence for an osteoclast origin of the giant cells.

Authors:  N A Athanasou; E Bliss; K C Gatter; A Heryet; C G Woods; J O McGee
Journal:  J Pathol       Date:  1985-11       Impact factor: 7.996

6.  Muramidase, alpha-1 antitrypsin, alpha-1 antichymotrypsin, and S-100 protein immunoreactivity in giant cell lesions.

Authors:  J A Regezi; R J Zarbo; R V Lloyd
Journal:  Cancer       Date:  1987-01-01       Impact factor: 6.860

7.  Giant cell tumor of bone: an immunohistochemical comparative study.

Authors:  F Masui; S Ushigome; K Fujii
Journal:  Pathol Int       Date:  1998-05       Impact factor: 2.534

8.  Proliferation index and vascular density of giant cell tumors of bone: are they prognostic markers?

Authors:  M A Sulh; M A Greco; T Jiang; S B Goswami; D Present; G Steiner
Journal:  Cancer       Date:  1996-05-15       Impact factor: 6.860

9.  Giant cell tumor of bone: a neoplasm or a reactive condition?

Authors:  Anwar Ul Haque; Ambreen Moatasim
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Clinical and immunohistochemical characteristics of benign giant cell tumour of bone with pulmonary metastases: case series.

Authors:  S Osaka; H Sugita; E Osaka; Y Yoshida; J Ryu; A Hemmi; K Suzuki
Journal:  J Orthop Surg (Hong Kong)       Date:  2004-06       Impact factor: 1.118

View more
  1 in total

1.  Flemingia philippinensis Flavonoids Relieve Bone Erosion and Inflammatory Mediators in CIA Mice by Downregulating NF-κB and MAPK Pathways.

Authors:  Guangchen Sun; Congcong Xing; Luting Zeng; Yijie Huang; Xin Sun; Yingqin Liu
Journal:  Mediators Inflamm       Date:  2019-02-17       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.